Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs
SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will...
News
Celsion GmbH Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer
LAWRENCEVILLE, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion...
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens
WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on...
Alignment Healthcare Announces Special Summer Tips to Help Seniors Beat the Heat, Stay Fit and Travel Safely
ORANGE, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- The Summer Solstice has officially ushered in the start of summer. That’s...
Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy
-Additional expertise expected to support attainment of key corporate goals- CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences...
Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs
REDWOOD CITY, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...
Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 1b trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC undergoing chemotherapy with first-line carboplatin plus pemetrexedStudy will...
Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products
Arthrex to receive exclusive rights to distribute and commercialize Celularity’s placental-derived biomaterial products for orthopedics and sport medicine in the...
scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®
FDA and Company in alignment on the path forward No additional clinical data or device modifications required at this time...
George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension
George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension Novel proprietary triple low-dose combination pill...
Nexstim Plc provides an update on the pilot study in chronic pain treatment at Helsinki University Hospital
Company announcement, Inside information, Helsinki, 1 July 2021 at 14.00 (EET) Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") provides an...
EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association
WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and...
Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends Baudax Bio Shareholders Vote “For” the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders
MALVERN, Pa., July 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing...
NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases
Merck and NGM will continue their research, discovery and development collaboration with a narrower scope, focused primarily on retinal and...
Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization...
Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress
AFM13 monotherapy: Reported positive outcome from the preplanned interim analysis for the registration-directed trial in PTCL; enrollment expected to be...
Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo
Formulation-related observations from ARQ-252 trial in chronic hand eczema informed early termination of Phase 2a ARQ-252 trial in vitiligoCompany progressing...
Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against SARS-CoV-2 Virus and Variants
Administration of OC-01 (varenicline) nasal spray to non-human primates was observed to inhibit viral replication in the nose within 24...
U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
– U.S. FDA has assigned a target action date of April 30, 2022 – – If approved, surufatinib would be HUTCHMED’s first novel...
Santa Ana CA Car Accident Injury Chiropractic Care/Pain Relief Treatments Launch
Dr Barry Marks Chiropractor announced that they are now providing an updated range of after-accident care treatments to patients in...